TCM
TCG Crossover Management Portfolio holdings
AUM
$876M
This Quarter Return
-20.68%
1 Year Return
+23.66%
3 Year Return
+996.72%
5 Year Return
–
10 Year Return
–
AUM
$733M
AUM Growth
+$733M
(-28%)
Cap. Flow
-$16.4M
Cap. Flow
% of AUM
-2.24%
Top 10 Holdings %
Top 10 Hldgs %
55.3%
Holding
38
New
–
Increased
2
Reduced
3
Closed
1
Top Buys
| 1 |
Tyra Biosciences
TYRA
|
$8.45M |
| 2 |
Amylyx Pharmaceuticals
AMLX
|
$4.6M |
Top Sells
| 1 |
Soleno Therapeutics
SLNO
|
$19.6M |
| 2 |
Keros Therapeutics
KROS
|
$8.71M |
| 3 |
Disc Medicine
IRON
|
$1.08M |
| 4 |
RAPT Therapeutics
RAPT
|
$55K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
CG Oncology
CGON
$2.04B
| $89.9M | 12.26% |
3,670,206
| – | – |
|
2
Cogent Biosciences
COGT
$1.69B
| $41.7M | 5.69% |
6,964,375
| – | – |
|
|
CNTA
3
Centessa Pharmaceuticals
CNTA
$2.25B
| $41.6M | 5.67% |
2,890,816
| – | – |
|
4
Mineralys Therapeutics
MLYS
$1.03B
| $39.2M | 5.35% |
2,470,265
| – | – |
|
5
Ocular Therapeutix
OCUL
$2.12B
| $39M | 5.32% |
5,319,148
| – | – |
|
|
ABVX
6
Abivax
ABVX
$6.12B
| $37.9M | 5.16% |
6,056,596
| – | – |
|
7
Savara
SVRA
$567M
| $34.2M | 4.67% |
12,362,205
| – | – |
|
8
Dyne Therapeutics
DYN
$1.92B
| $27.7M | 3.78% |
2,650,150
| – | – |
|
9
Dianthus Therapeutics
DNTH
$759M
| $27.2M | 3.72% |
1,501,624
| – | – |
|
|
10
Tyra Biosciences
TYRA
$675M
| $27M | 3.68% |
2,898,103
+909,000
| +46% | +$8.45M |
|
11
Xencor
XNCR
$580M
| $26.1M | 3.56% |
2,452,138
| – | – |
|
|
12
Disc Medicine
IRON
$2.07B
| $23.1M | 3.15% |
465,257
-21,700
| -4% | -$1.08M |
|
13
Tourmaline Bio
TRML
$601M
| $22.5M | 3.07% |
1,477,593
| – | – |
|
14
Cidara Therapeutics
CDTX
$1.66B
| $21.7M | 2.96% |
1,005,901
| – | – |
|
|
15
Amylyx Pharmaceuticals
AMLX
$836M
| $21M | 2.87% |
5,943,812
+1,300,000
| +28% | +$4.6M |
|
|
16
Soleno Therapeutics
SLNO
$3.6B
| $19.6M | 2.68% |
275,000
-275,000
| -50% | -$19.6M |
|
17
EyePoint Pharmaceuticals
EYPT
$797M
| $19.4M | 2.64% |
3,572,335
| – | – |
|
18
Structure Therapeutics
GPCR
$1.11B
| $18.4M | 2.51% |
1,063,000
| – | – |
|
|
UPB
19
Upstream Bio, Inc. Common Stock
UPB
$923M
| $17.1M | 2.34% |
2,801,763
| – | – |
|
|
20
RAPT Therapeutics
RAPT
$188M
| $16M | 2.18% |
13,090,200
-45,060
| -0.3% | -$55K |
|
21
Fulcrum Therapeutics
FULC
$351M
| $15.1M | 2.06% |
5,250,000
| – | – |
|
22
Astria Therapeutics
ATXS
$349M
| $14.7M | 2.01% |
2,761,861
| – | – |
|
23
Tango Therapeutics
TNGX
$747M
| $14.7M | 2.01% |
10,736,000
| – | – |
|
|
CMPS
24
Compass Pathways
CMPS
$424M
| $11M | 1.51% |
3,858,000
| – | – |
|
25
Kura Oncology
KURA
$686M
| $9.4M | 1.28% |
1,423,642
| – | – |
|